Stock Analysis on Net

IQVIA Holdings Inc. (NYSE:IQV)

$22.49

This company has been moved to the archive! The financial data has not been updated since November 1, 2023.

Enterprise Value to FCFF (EV/FCFF)

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Free Cash Flow to The Firm (FCFF)

IQVIA Holdings Inc., FCFF calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Net income attributable to IQVIA Holdings Inc.
Net income attributable to non-controlling interests
Net noncash charges
Changes in operating assets and liabilities
Net cash provided by operating activities
Interest paid, net, net of tax1
Acquisition of property, equipment and software
Right-of-use assets obtained in exchange for finance lease obligations
Free cash flow to the firm (FCFF)

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).


The analysis of the annual financial data reveals several key trends in the cash flow activities over the five-year period ending December 31, 2022.

Net Cash Provided by Operating Activities
The net cash provided by operating activities shows a generally upward trend from 2018 to 2021, increasing from $1,254 million to $2,942 million. This represents a substantial growth, more than doubling over three years, which suggests improved operational efficiency or increased cash-generating capacity. However, in 2022, there is a noticeable decline to $2,260 million, indicating some weakening in operating cash flow compared to the previous year. Despite this decrease, the level remains higher than in the years prior to 2021, suggesting sustained overall strength in operations relative to the earlier part of the period.
Free Cash Flow to the Firm (FCFF)
Free cash flow to the firm follows a similar trend, increasing modestly from $1,121 million in 2018 to $1,117 million in 2019, indicating stability in free cash generation. From 2019 through 2021, FCFF rises significantly, reaching a peak of $2,551 million in 2021, aligning closely with the pattern observed in operating cash flow. In 2022, FCFF decreases to $1,839 million, mirroring the decline in net cash provided by operating activities. This reduction may be attributed to changes in capital expenditures or operational cash generation but still represents a solid level of free cash flow generation relative to earlier years.

Overall, both operating cash flow and free cash flow show strong growth through 2021, reflecting enhanced financial performance and potentially increased investment capacity. The decline in 2022 signals a need for further analysis to understand underlying causes, but the company's cash flow generation remains robust compared to the starting point in 2018.


Interest Paid, Net of Tax

IQVIA Holdings Inc., interest paid, net of tax calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Effective Income Tax Rate (EITR)
EITR1
Interest Paid, Net of Tax
Interest paid, net, before tax
Less: Interest paid, net, tax2
Interest paid, net, net of tax

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 See details »

2 2022 Calculation
Interest paid, net, tax = Interest paid, net × EITR
= × =


The effective income tax rate (EITR) displayed notable fluctuations over the analyzed periods. Initially, it was at 17.99% at the end of 2018, then rose significantly to 32.95% by the end of 2019. Subsequently, it declined sharply to 19.3% in 2020 and continued to decrease to a low of 14.45% in 2021. In 2022, there was a moderate increase again, with the rate reaching 19.08%. This pattern suggests a period of increased tax expense in 2019, followed by tax relief or improved tax efficiency in the following two years, and a slight upward adjustment in the latest period.

Net interest paid, net of tax, also demonstrated some variability but within a relatively narrow range. The amount was US$326 million in 2018, decreased to US$282 million in 2019, then rose to US$322 million in 2020. A subsequent decline to US$293 million occurred in 2021, followed by a modest increase to US$307 million in 2022. Overall, the interest expense appears to have fluctuated in response to changes in debt levels or interest rates but remained generally stable over the five-year span.

Effective Income Tax Rate (EITR)
Initial increase from 17.99% to 32.95% in 2019.
Significant decrease over the next two years to 14.45% in 2021.
Moderate increase to 19.08% by the end of 2022.
Interest Paid, Net of Tax (US$ millions)
Decreased from 326 in 2018 to 282 in 2019.
Increase to 322 in 2020 followed by a decline to 293 in 2021.
Slight increase again to 307 in 2022.

Enterprise Value to FCFF Ratio, Current

IQVIA Holdings Inc., current EV/FCFF calculation, comparison to benchmarks

Microsoft Excel
Selected Financial Data (US$ in millions)
Enterprise value (EV)
Free cash flow to the firm (FCFF)
Valuation Ratio
EV/FCFF
Benchmarks
EV/FCFF, Competitors1
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.
EV/FCFF, Sector
Pharmaceuticals, Biotechnology & Life Sciences
EV/FCFF, Industry
Health Care

Based on: 10-K (reporting date: 2022-12-31).

1 Click competitor name to see calculations.

If the company EV/FCFF is lower then the EV/FCFF of benchmark then company is relatively undervalued.
Otherwise, if the company EV/FCFF is higher then the EV/FCFF of benchmark then company is relatively overvalued.


Enterprise Value to FCFF Ratio, Historical

IQVIA Holdings Inc., historical EV/FCFF calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Selected Financial Data (US$ in millions)
Enterprise value (EV)1
Free cash flow to the firm (FCFF)2
Valuation Ratio
EV/FCFF3
Benchmarks
EV/FCFF, Competitors4
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.
EV/FCFF, Sector
Pharmaceuticals, Biotechnology & Life Sciences
EV/FCFF, Industry
Health Care

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 See details »

2 See details »

3 2022 Calculation
EV/FCFF = EV ÷ FCFF
= ÷ =

4 Click competitor name to see calculations.


The financial data reveals several notable trends over the five-year period from 2018 to 2022. The enterprise value (EV) exhibits a general upward trend from 38,267 million USD in 2018, reaching a peak of 55,061 million USD in 2021, before experiencing a slight decrease to 53,832 million USD in 2022. This pattern suggests overall growth in company valuation with a marginal decline in the most recent year.

Free cash flow to the firm (FCFF) demonstrates an increasing trajectory from 1,121 million USD in 2018 to a high of 2,551 million USD in 2021, followed by a reduction to 1,839 million USD in 2022. Despite the decline in 2022, the company’s FCFF in that year remains significantly higher than the values recorded in 2018 and 2019, indicating an improvement in cash generation capacity over the medium term.

The EV/FCFF ratio, which measures the firm's valuation relative to its free cash flow, reflects notable fluctuations. Starting at 34.12 in 2018, the ratio rises to 38.33 in 2019, suggesting increased valuation pressure relative to cash flow. Subsequently, it declines steadily to 21.58 in 2021, indicating a more favorable valuation relative to cash flow that year. However, the ratio increases again to 29.28 in 2022, implying a partial reversal of the earlier improved valuation status.

Overall, the data points to a period of expansion and improved cash flow efficiency culminating in 2021, followed by a normalization or slight downturn in 2022 in terms of both valuation and cash flow generation. The fluctuations in the EV/FCFF ratio suggest changing market perceptions or operational dynamics influencing the firm’s valuation relative to its cash flow performance.